Figure 3From: Enhancement of anti-murine colon cancer immunity by fusion of a SARS fragment to a low-immunogenic carcinoembryonic antigenIn vivo tumor development of BALB/c mice after oral vaccination. Five BALB/c mice in each treatment group were inoculated with CT26/CEA cells 21 days after vaccination with pCEA- and pCEA-SARS-transformed S. typhimurium and the tumor volume in the mice was observed. (*, p < 0.05 in comparison with the control and the pCEA group).Back to article page